Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on March 11, 2008
JNCI Journal of the National Cancer Institute 2008 100(6):445-446; doi:10.1093/jnci/djn021
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/6/445    most recent
djn021v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Stewart, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Stewart, D. J.
Related Collections
Right arrowRelated Article in JNCI
Right arrowResponse to this Correspondence
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press.

CORRESPONDENCE

Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non–Small Cell Lung Cancer

David J. Stewart

Affiliation of author: Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX

Correspondence to: David J. Stewart, MD, FRCPC, Professor of Medicine, Department of Thoracic/Head and Neck Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 (e-mail: dstewart@mdanderson.org).

The first 10% of the full text of this article appears below.

In their recent article in the Journal (1), Karrison et al. outline a number of possible advantages of reporting response as a . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non–Small-Cell Lung Cancer
Theodore G. Karrison, Michael L. Maitland, Walter M. Stadler, and Mark J. Ratain
J Natl Cancer Inst 2007 99: 1455-1461. [Abstract] [Full Text] [PDF]

Response to this Correspondence

Response: Re: Design of Phase II Cancer Trials Using a Continuous Endpoint of Change in Tumor Size: Application to a Study of Sorafenib and Erlotinib in Non–Small Cell Lung Cancer
Theodore Karrison, Michael Maitland, Walter Stadler, and Mark J. Ratain
J Natl Cancer Inst 2008 100: 446. [Extract] [Full Text] [PDF]